about
Overview of current immunotherapeutic strategies for gliomaHPV Carcinomas in Immunocompromised PatientsSkin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cellsEnv-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virusTreatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccinationImiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cellsTopical imiquimod has therapeutic and immunomodulatory effects against intracranial tumorsHuman in vitro skin organ culture as a model system for evaluating DNA repair.Immunomodulation by imiquimod in patients with high-risk primary melanomaIL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses.A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's diseaseInhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.Autophagy links pattern recognition receptors to tumor cell apoptosis.In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation.Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction
P2860
Q26776345-7E1D6B95-CB3F-492A-9094-E4B1EA8D8DCCQ26799629-7320CABD-0B04-46D5-B9FB-59E0F5A9F55AQ27323190-8301BD46-C663-4E93-B37A-155814E30786Q33769283-D110D01D-4FA5-471C-8705-5A1120D05DC5Q33864400-01340F76-B14E-4505-8571-B90F72F15092Q33963409-88527219-A159-47A1-9D50-B157618B99C6Q34777706-0DE26BCD-F25B-4EBF-B756-5302A95D8D53Q35013278-9E6E2B3F-6957-4698-960B-5737947A8B10Q35590166-D4B59592-ECDD-41AB-90E0-7DECC35F8E13Q35621594-6D48961F-0B4D-4DE8-88BB-80C57366071BQ37029765-6009E48B-2579-4BB7-98DD-9EAAA97511BDQ38363654-F3FDDBC8-8407-49D4-87B3-A81E8008E5E0Q39502795-103B1BBD-8044-4983-8FD6-45C71FCA2659Q40937108-CE521184-208A-478B-B0CB-C686F4B31002Q41349651-31DAEDD0-43F7-4F34-9EA2-350F2FBD7E6CQ41979125-E12B1490-713B-4631-8109-6DD0D51D573EQ42245457-503EAAF3-041B-47B9-9506-A11473ECE848
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Beyond a decade of 5% imiquimod topical therapy.
@en
Beyond a decade of 5% imiquimod topical therapy.
@nl
type
label
Beyond a decade of 5% imiquimod topical therapy.
@en
Beyond a decade of 5% imiquimod topical therapy.
@nl
prefLabel
Beyond a decade of 5% imiquimod topical therapy.
@en
Beyond a decade of 5% imiquimod topical therapy.
@nl
P2093
P1476
Beyond a decade of 5% imiquimod topical therapy
@en
P2093
Anthony A Gaspari
Stephen K Tyring
Theodore Rosen
P304
P577
2009-05-01T00:00:00Z